Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 8/20 | 0.43 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718079 | 0.90 | PPARA (0.53) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6713421 | 0.82 | KMT2A (0.47) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6713537 | 0.81 | OPRK1 (0.49) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6715972 | 0.80 | OPRK1 (0.48) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6715187 | 0.79 | MEN1 (0.50) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6715217 | 0.79 | OPRK1 (0.45) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6715183 | 0.77 | OPRK1 (0.53) | PPARAPPARGPPARDOPRK1NPC1 | |
| SCHEMBL6718042 | 0.76 | CA12 (0.47) | PPARAPPARGPPARDOPRK1NPC1 | |
| SCHEMBL6715028 | 0.76 | MEN1 (0.48) | KMT2AMEN1PPARAPPARGPPARD | |
| SCHEMBL6713362 | 0.75 | RXRA (0.55) | PPARAPPARGOPRK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | KMT2A 3611/4885MEN1 3916/4885PPARA 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.